Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Nutraceutical
- Food
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.
IPSCIO Record ID: 5244
License Grant
The Company’ newly acquired subsidiary, exclusively licensed patents related to amino acid based dietary supplements to enhance the level of endogenous nitric oxide in the vascular system from the University.
IPSCIO Record ID: 4735
License Grant
The Licensor was assigned the License agreement related to dietary supplements and drugs, by the original Licensor in a Stock Purchase Agreement.
License Property
Dietary supplements including glucan and fulvic acid and herbal enhanced analgesic formulations.
Field of Use
Licensee is a biotechnology company engaged in the research and development, marketing and sale of lifestyle, dietary supplements and drugs.
IPSCIO Record ID: 221856
License Grant
Licensor hereby grants to Licensee a nonexclusive license under the Licensed Patents to make, have made, use, offer to sell, sell, and import Licensed Products within the Field of Use throughout the world for the Term of this License Agreement.
License Property
Licensee sells certain nutritional supplements containing the amino acid L-Arginine, Licensee admits that the sale of its L-Arginine containing products infringes certain claims contained in the Issued Patents (the ‘Infringed Claims’), Licensee admits the validity and enforceability of the Issued Patents and Licensee desires to obtain a nonexclusive license to the Issued Patents so that it may continue selling products containing L-Arginine in accordance with this License Agreement.
‘Licensed Patents’ means the Issued Patents and any patents that hereafter issue in the United States from applications pending before the U.S. Patent and Trademark Office as herein described, and any other patents issued or licensed to, or acquired by, Licensor in the United States or elsewhere in the world that relate to composition of L-Arginine Based Products, or to any method of orally administering L-Arginine Based Products. Without limiting the generality of the foregoing, Licensed Patents shall include any patent issuing pursuant to U.S. Patent Application No. 10/060,252 entitled ‘Enhancement of Vascular Function by Modulation of Endogenous Nitric Oxide Production or Activity’ filed February 1, 2002 (the ‘Pending Application’).
‘L-Arginine-Based Products’ means products intended for human consumption that contain the amino acid L-Arginine, including but not limited to salts and peptides or other compositions in which L-Arginine may be bonded to other moieties, as an ingredient for enhancing nitric oxide, reducing vascular resistance, increasing blood flow, and/or enhancing physical performance.
‘Cardiovascular’ means referring or relating to the human heart and circulatory system including veins, arteries, and capillaries, and further including references to diseases of the human cardiovascular system.
Field of Use
The ‘Field of Use’ is enhancing human sexual performance, specifically nutritional supplements that are offered, promoted and/or marketed as enhancing human sexual performance through products containing L-Arginine or oral administration of L-Arginine. Field of Use shall include and permit Cardiovascular claims that are limited to human sexual performance as specifically permitted in Article VII of this License Agreement.
IPSCIO Record ID: 968
License Grant
The Company’s subsidiary modified a License Agreement a company controlled by Company’s Chairman and Chief Executive Officer. The License Agreement, originally entered into in May 1997, licenses the Company’s patent rights for the oral delivery of lipophilic substances.
Field of Use
The rights granted apply in the limited field of nutraceuticals, which include food and dietary supplements, food additives, vitamins and herbs.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
